SEC Form 4 · accession 0000059478-16-000308

ELI LILLY & Co · LLY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP and Pres, Lilly Bio-Meds

Period of report

Feb 1, 2016

Accepted (ET)

Feb 3, 2016 · 2:04 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000059478

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Feb 1, 2016	M	9,843	$0.00	A	89,792	D
Common Stock	Feb 1, 2016	F	4,656	$79.10	D	85,136	D
Common Stock^F2	Feb 1, 2016	S	3,273	$78.36	D	81,863	D
Common Stock^F3	Feb 3, 2016	S	2,460	$76.73	D	79,403	D
Common Stock	holding	—	—		—	4,222	I	401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F4	—	Feb 1, 2016	M	9,843	D	Feb 1, 2016	Feb 1, 2016	Common Stock	9,843	0	D

F1The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2015.
F2This transaction was executed in multiple trades at prices ranging from $78.19 to $78.61. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $76.46 to $76.92. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.